key: cord-0692769-tfz3rfr9
authors: Yang, Eunice; Marine, Joseph E.
title: Editorial commentary: Hitting a moving target: The challenge of creating consensus treatment protocols for cardiovascular care during the coronavirus pandemic
date: 2020-06-17
journal: Trends Cardiovasc Med
DOI: 10.1016/j.tcm.2020.06.002
sha: b2adeeb7320399e0739cb9b3ba2fb58f5eed84b0
doc_id: 692769
cord_uid: tfz3rfr9

nan

The severe acute respiratory virus 2 (SARS-CoV2) infection has swept across the world through the first half of 2020, leading to significant loss of life, economic hardship, and social disruption. Our global medical community has been working at the frontlines against the COVID-19 pandemic. Scientists across the world have worked to develop our understanding of the virus, with the goal of identifying preventative and therapeutic treatments. As this search continues, healthcare professionals have rallied at the bedside, making efforts to maintain quality of patient care while mitigating risk of viral spread to both patients and clinicians.

The rapid, adaptive change needed to care for both COVID and non-COVID patients has thus far outpaced the creation of consensus guidelines for care in the COVID-19 era. Yet, as the pandemic continues to unfold, these preliminary adaptive measures created by each institution will need to evolve in concert with the growing data surrounding treatment and protection. As such, there is a clear need to develop a framework for best-practice clinical guidance in the COVID-19 era.

The broad-reaching effects of the COVID-19 pandemic require that all clinicians remain informed of continued developments in care as we broaden our understanding of the disease. In addition, cardiologists should remain up-to-date on the latest developments for three main reasons: (1) consistently reported cardiovascular manifestations of the SARS-CoV2 infection; (2) care of non-COVID related cardiovascular comorbidities in patients who are concomitantly infected with COVID-19; and (3), balanced risk assessments for patients with cardiovascular conditions, which requires weighing risk of exposure to COVID-19 against need for timely cardiovascular assessment and intervention. To address these three points, Ganatra and colleagues in this issue of Trends in Cardiovascular Medicine summarize briefly the state of our clinical understanding of COVID-19, and then offer concise clinical guidance using text and flowcharts based on the current data available from both literature review and their own clinical experience [1] .

Although the most frequent complication reported with COVID-19 infections is respiratory failure, many cardiac manifestations * Corresponding author. have been noted. Acute cardiac injury, defined variably in various studies, has been reported in 7-33% of all hospitalized patients [ 2 , 3 ] . Other cardiovascular sequelae have also been reported, from general "arrhythmias" in 17% of non-ICU inpatients to up to 44% in ICU admissions to reports of sustained ventricular tachycardia or ventricular fibrillation amongst 6% of COVID patients [4] . Heart failure has been variably reported, including presentations with acute myocarditis and stress cardiomyopathy [ 5 , 6 ] . COVID-19 patients also have a high propensity for developing thrombosis, leading to hemodynamic consequences that require cardiovascular care [7] . In sum, some COVID-19 patients may have cardiovascular manifestations that we have only begun to understand, both in mechanism of injury and long-term consequences following convalescence. All these emerging conditions, described succinctly by Ganatra and colleagues, require clinical management skills and longterm care by cardiologists.

The authors proceed to address management of cardiovascular conditions in patients who test positive for COVID-19 infection, focusing on the need for timely interventions while taking protective measures to minimize exposure and spread of infection. The flowcharts they have constructed are particularly useful. Nonemergent cases are recommended to be scheduled later in the day to reduce the number of clinicians and ancillary staff members in the operating rooms and minimize the need for terminal cleaning. For management of cardiovascular patients who do not have concomitant COVID-19, efforts have been directed towards providing excellent care while mitigating exposure risk. Guidance is provided for COVID-19 patients with elevated troponin, those with myocardial injury or acute MI, and those with cardiogenic shock.

The authors conclude by cautioning clinicians on latepresentations of time-sensitive cardiovascular complaints, noting that patients have been reluctant to seek medical attention during pandemic for fear of contracting an infection in the healthcare setting. This observation, the authors stress, should raise concerns regarding late manifestations of myocardial infarction, heart failure, and arrhythmias, but also put physicians on high alert in speaking with their patients to promptly address any cardiovascular complaints. Patients with urgent and emergent cardiovascular complaints should still be encouraged to seek emergency care. Telemedicine visits, where possible, have increased for routine pa-tient management, providing patients with more convenient and timely access to their health care professionals.

Limitations of this review include those common to most COVID-19 related publications: the dearth of data presently available, rapid publication and dissemination of new information, as well as concerns about the reliability of this information. One example is the recent controversy surrounding the role of hydroxychloroquine, which has had conflicting reports of efficacy, no benefit, and potential harm for COVID-19 [8] [9] [10] . Critical appraisal of these studies has led to controversy surrounding the quality of the data as well as the reliability of data analyses performed [11] . In an information-poor health crisis, the rush to produce and publish data places the medical community at risk of relying on evidence that has not undergone the same rigors of inspection, review, and confirmation. Ganatra and colleagues are appropriately measured in their recommendations. Their clinical guidance is concise, common-sense, rational, and adaptable to individual practice situations. Striking an appropriate balance between speed and rigor in translating scientific and clinical findings on SARS-CoV2 infection to practice guidelines will be paramount to providing reliable advice to patients and clinicians.

The COVID-19 pandemic has required rapid adaptation of clinical care across the world. However, there has been a paucity of consensus guidelines addressing management of both COVID patients with cardiovascular disease, as well as non-COVID related medical care in this time of heightened concern for infectious risk. Ganatra and colleagues present a timely overview of the current literature on cardiovascular care during the COVID-19 era, and offer recommendations for clinical care regarding both cardiovascular complications from COVID-19 infection, as well as suggestions on maintaining high quality clinical care while minimizing viral exposure. Their review is an ambitious one, and particularly challenging in the face of our rapidly evolving understanding of COVID-19. The premise of their review is equally challenging, as we anticipate that new medical knowledge and regulatory changes could render some recommendations obsolete. Yet, despite such limitations, it has never been more valuable to have clinicians up to date with best available information, and we commend the authors for their effort s and success in their review.

Management of cardiovascular disease during coronavirus disease (COVID-19) pandemic

Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington state

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan

Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19)

Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19)

Takotsubo syndrome in the setting of COVID-19 infection

May 1 Online ahead of print

ISTH interim guidance on recognition and management of coagulopathy in COVID-19

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial

Retraction-Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis